On September 14, 2026, the trial registry listed an update for the study titled "Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery," registered as NCT03070886. This trial involves degarelix as part of an antiandrogen therapy approach. The study is listed as Phase 2/Phase 3.
Its current status is active, not recruiting, meaning the trial is ongoing but no longer enrolling new participants. The trial evaluates antiandrogen therapy combined with radiation therapy, with or without docetaxel, in patients who have undergone surgical removal of prostate cancer.
No results have been reported in this update. The status change reflects only the recruitment phase of the trial, not any outcome or efficacy data. Readers should not interpret this update as evidence of benefit or harm related to degarelix or the other therapies studied.
Further updates may follow as the trial progresses through its active phase. For more background on degarelix, including its approved uses and general profile, see the compound overview.